.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Julphar
Harvard Business School
Colorcon
Farmers Insurance
Cipla
Baxter
Moodys
Mallinckrodt
Covington

Generated: July 23, 2017

DrugPatentWatch Database Preview

Lenvatinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lenvatinib mesylate and what is the scope of lenvatinib mesylate freedom to operate?

Lenvatinib mesylate
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenvatinib mesylate has one hundred and one patent family members in thirty countries.

One supplier is listed for this compound.

Summary for Generic Name: lenvatinib mesylate

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list5
Clinical Trials: see list563
Patent Applications: see list11
Drug Prices:see low prices
DailyMed Link:lenvatinib mesylate at DailyMed

Pharmacology for Ingredient: lenvatinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes7,612,208► SubscribeYY ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo7,612,208► SubscribeYY ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lenvatinib mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,092Nitrogen-containing aromatic derivatives► Subscribe
8,372,981Nitrogen-containing aromatic derivatives► Subscribe
7,973,160Nitrogen-containing aromatic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lenvatinib mesylate

Country Document Number Estimated Expiration
Israel195282► Subscribe
China101029022► Subscribe
HungaryE025742► Subscribe
Hong Kong1102027► Subscribe
Japan3712393► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LENVATINIB MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0764Netherlands► SubscribePRODUCT NAME: LENVATINIB, EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1002/001 -002 20150528
90053-3Sweden► SubscribePRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REG. NO/DATE: EU/1/15/1002 20150601
858Luxembourg► SubscribePRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI
2015039Lithuania► SubscribePRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
C0070France► SubscribePRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
Fuji
Citi
Harvard Business School
Julphar
Cantor Fitzgerald
Accenture
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot